Reuters logo
BRIEF-Zogenix Announces New Data From Pivotal Phase 3 Clinical Trial Of ZX008
December 4, 2017 / 1:18 PM / 12 days ago

BRIEF-Zogenix Announces New Data From Pivotal Phase 3 Clinical Trial Of ZX008

Dec 4 (Reuters) - Zogenix Inc:

* ZOGENIX ANNOUNCES NEW POSITIVE EFFICACY AND SAFETY DATA FROM PIVOTAL PHASE 3 CLINICAL TRIAL OF ZX008 IN DRAVET SYNDROME

* ZOGENIX INC - DATA SHOWS ZX008 PATIENTS MORE LIKELY TO ACHIEVE CLINICALLY MEANINGFUL REDUCTION IN SEIZURE FREQUENCY COMPARED TO THOSE ON PLACEBO

* ZOGENIX INC - LOOK FORWARD TO SHARING TOP-LINE RESULTS FROM SECOND PIVOTAL PHASE 3 TRIAL OF ZX008, STUDY 1504, IN Q2 OF 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below